Table 4.
Selected SBRT series in patients with primary and secondary liver tumors
| Author, Year Study-Type |
n (patients) n (lesions) |
n (primary LT) n (metastases) |
GTV volume (median/range)a | 1 yr-LC (%) (HCC/MD) | 1 yr-OS (%) (HCC/MD) |
Toxicity Gr3+ (%) |
|---|---|---|---|---|---|---|
| Mendez-Romero et al. 2006 Phase I/II |
25 45 |
HCC: 11 MD: 34 |
3.5 (0.5–7.2) | 94 (75/100) |
82 (75/85) |
12.5 |
| Goodman et al. 2010 Phase I |
26 40 |
HCC/CCC: 7 MD: 19 |
32.6 (0.8–146.6) | 77 | 62 | 0 |
| Own data | 55 70 |
HCC: 27 MD: 28 |
6.6 (0.2–204) | 91 (92/89) |
76 (68/84) |
5b |
| Bujold et al. 2013 Phase I/II |
102 | HCC only | 7.2 (1.4–23.1) | 87 | 55 | 30 |
| Lasley et al. 2015 Phase I/II |
59 59 |
HCC only | 33.6 (2.2–107.3) | 91 (Child A) 82 (Child B) |
94 (Child A) 57 (Child B) |
11 (Child A) 38 (Child B) |
| Own data | 27 36 |
HCC only | 7.5 (0.9–204) | 92 | 68 | 11b |
| Scorsetti et al. 2015 Phase I/II |
42 52 |
MD only | 3.5 (1.1–5.4) | 91 (2 yr) | 65 (2 yr) | 0 |
| Andratschke et al. 2015 Retro, pooled |
74 91 |
MD only | n.r. | 75 | 77 | 0 |
| Own data | 28 34 |
MD only | 6.2 (0.2–98.2) | 89 | 84 | 0 |
n: number, LT: liver tumors, GTV: gross tumor volume per lesion, yr.: year, LC: local control, OS: overall survival, HCC: hepatocellular carcinoma, MD: metastatic disease, Gr3+: grade 3+, a in cubic centimeters, b: deterioration of liver function, no other grade 3+ toxicity, n.r.: not reported